IPO - China SXT Pharmaceuticals, Inc.

Form Type: 424B5

Filing Date: 2025-05-19

Corporate Action: Ipo

Type: New

Accession Number: 000121390025045088

Filing Summary: On May 16, 2025, China SXT Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with investors to offer 10,000,000 Ordinary Shares and warrants to purchase up to an additional 100,000,000 Ordinary Shares, with no par value. The shares and related warrants are being sold at a combined offering price of $0.51 for each share and associated warrants. The warrants will have an exercise price of $1.20 per share and will be immediately exercisable upon issuance, expiring five years from issuance. The exercise price of these warrants may be reset on a specified date to a minimum of $0.24 if the company's securities meet certain conditions. This financing aims to provide funds primarily for the development and commercialization of projects, working capital, and general corporate purposes. As of the offering date, the last reported sale price of the shares was $1.20, and the total gross proceeds anticipated from this offering are approximately $5,100,000. Given the company's structure as a holding company incorporated in the British Virgin Islands, it conducts operations through VIE agreements with subsidiaries in China, raising specific regulatory concerns regarding foreign investments and compliance with Chinese laws. Investment in China SXT carries significant risks related to its corporate structure, operational efficiency in China, and external economic conditions that could impact the value and viability of its ordinary shares.